Sheppard Mullin represented Aridis Pharmaceuticals on the deal Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using…
Aridis Pharmaceuticals’ $26 Million Initial Public Offering
![](https://globallegalchronicle.com/wp-content/uploads/2018/09/c299e24ce3.jpeg)